Table 1
Open in new tab

Characteristics of MRI-PDFF and FLI cohorts

UKBB MRI-PDFF imaging cohort (n = 16,050)UKBB FLI phenotype cohort (n = 388,701)UGLI FLI replication cohort (n = 10,398)
Characteristics
Age (year): median (IQR)56 (49–61)58 (51–63)42 (32–50)
Sex: men/women, n (%)7647 (47.6) / 8403 (52.4)178,624 (46.0) / 210,007 (54.0)4220 (40.6) / 6178 (59.4)
BMI (kg/m2): median (IQR)26.0 (23.7–28.8)26.7 (24.2–29.9)25.1 (22.8–27.7)
BMI

  • Normal (≤ 25 kg/m2): n (%)

6207 (38.7)128,238 (33.0)5115 (49.2)

  • Overweight (25–30 kg/m2): n (%)

6978 (43.5)166,322 (42.8)3966 (38.1)

  • Obese (≥ 30 kg/m2): n (%)

2841 (17.7)94,141 (24.2)1316 (12.7)
Waist circumference

  • Men (cm): median (IQR)

94.0 (88.0–101.0)96.0 (89.0–104.0)94.0 (87.0–101.0)

  • Women (cm): median (IQR)

80.0 (74.0–88.0)83.0 (75.0–92.0)84.0 (77.0–93.0)
Metabolic comorbid diseases

  • T2DM: n (%)

449 (2.8)19,040 (4.9)235 (2.3)

  • MetS: n (%)

1827 (11.4)67,304 (17.3)1440 (13.8)
Hepatic fat content phenotypes
FLI: median (IQR)38.8 (16.2–67.3)46.4 (20.0–75.7)23.6 (9.8–51.0)

  • FLI < 30: n (%)

6333 (39.5)137,611 (35.4)6002 (57.7)

  • FLI ≥ 60: n (%)

4721 (29.4)149,672 (38.5)1988 (19.1)
MRI-PDFF (%): median (IQR)2.8 (1.9–5.2)N.A.N.A.
UKBB MRI-PDFF imaging cohort (n = 16,050)UKBB FLI phenotype cohort (n = 388,701)UGLI FLI replication cohort (n = 10,398)
Characteristics
Age (year): median (IQR)56 (49–61)58 (51–63)42 (32–50)
Sex: men/women, n (%)7647 (47.6) / 8403 (52.4)178,624 (46.0) / 210,007 (54.0)4220 (40.6) / 6178 (59.4)
BMI (kg/m2): median (IQR)26.0 (23.7–28.8)26.7 (24.2–29.9)25.1 (22.8–27.7)
BMI

  • Normal (≤ 25 kg/m2): n (%)

6207 (38.7)128,238 (33.0)5115 (49.2)

  • Overweight (25–30 kg/m2): n (%)

6978 (43.5)166,322 (42.8)3966 (38.1)

  • Obese (≥ 30 kg/m2): n (%)

2841 (17.7)94,141 (24.2)1316 (12.7)
Waist circumference

  • Men (cm): median (IQR)

94.0 (88.0–101.0)96.0 (89.0–104.0)94.0 (87.0–101.0)

  • Women (cm): median (IQR)

80.0 (74.0–88.0)83.0 (75.0–92.0)84.0 (77.0–93.0)
Metabolic comorbid diseases

  • T2DM: n (%)

449 (2.8)19,040 (4.9)235 (2.3)

  • MetS: n (%)

1827 (11.4)67,304 (17.3)1440 (13.8)
Hepatic fat content phenotypes
FLI: median (IQR)38.8 (16.2–67.3)46.4 (20.0–75.7)23.6 (9.8–51.0)

  • FLI < 30: n (%)

6333 (39.5)137,611 (35.4)6002 (57.7)

  • FLI ≥ 60: n (%)

4721 (29.4)149,672 (38.5)1988 (19.1)
MRI-PDFF (%): median (IQR)2.8 (1.9–5.2)N.A.N.A.

Note: Data are given in number with percentage (%) or median with IQR. T2DM was confirmed when a subject had either self-reported on T2DM, used glucose lowering medication, had fasting glucose ≥ 7.0 mmol/l, or had HbA1c ≥ 47.5 mmol/mol (6.5%). Metabolic syndromes were defined according to NCEP ATPIII criteria. UKBB MRI-PDFF imaging cohort includes UKBB imaging subset 1 (Data field 22436) and UKBB imaging subset 2 (return data ID 2342). MRI-PDFF, magnetic resonance imaging proton density fat fraction; FLI, fatty liver index; UKBB, UK Biobank; UMCG, University Medical Center Groningen; UGLI, UMCG Genetics Lifelines Initiative; IQR, interquartile range; BMI, body mass index; T2DM, type 2 diabetes mellitus; MetS, metabolic syndrome; NCEP, National Cholesterol Education Program; N.A., not available.

Table 1
Open in new tab

Characteristics of MRI-PDFF and FLI cohorts

UKBB MRI-PDFF imaging cohort (n = 16,050)UKBB FLI phenotype cohort (n = 388,701)UGLI FLI replication cohort (n = 10,398)
Characteristics
Age (year): median (IQR)56 (49–61)58 (51–63)42 (32–50)
Sex: men/women, n (%)7647 (47.6) / 8403 (52.4)178,624 (46.0) / 210,007 (54.0)4220 (40.6) / 6178 (59.4)
BMI (kg/m2): median (IQR)26.0 (23.7–28.8)26.7 (24.2–29.9)25.1 (22.8–27.7)
BMI

  • Normal (≤ 25 kg/m2): n (%)

6207 (38.7)128,238 (33.0)5115 (49.2)

  • Overweight (25–30 kg/m2): n (%)

6978 (43.5)166,322 (42.8)3966 (38.1)

  • Obese (≥ 30 kg/m2): n (%)

2841 (17.7)94,141 (24.2)1316 (12.7)
Waist circumference

  • Men (cm): median (IQR)

94.0 (88.0–101.0)96.0 (89.0–104.0)94.0 (87.0–101.0)

  • Women (cm): median (IQR)

80.0 (74.0–88.0)83.0 (75.0–92.0)84.0 (77.0–93.0)
Metabolic comorbid diseases

  • T2DM: n (%)

449 (2.8)19,040 (4.9)235 (2.3)

  • MetS: n (%)

1827 (11.4)67,304 (17.3)1440 (13.8)
Hepatic fat content phenotypes
FLI: median (IQR)38.8 (16.2–67.3)46.4 (20.0–75.7)23.6 (9.8–51.0)

  • FLI < 30: n (%)

6333 (39.5)137,611 (35.4)6002 (57.7)

  • FLI ≥ 60: n (%)

4721 (29.4)149,672 (38.5)1988 (19.1)
MRI-PDFF (%): median (IQR)2.8 (1.9–5.2)N.A.N.A.
UKBB MRI-PDFF imaging cohort (n = 16,050)UKBB FLI phenotype cohort (n = 388,701)UGLI FLI replication cohort (n = 10,398)
Characteristics
Age (year): median (IQR)56 (49–61)58 (51–63)42 (32–50)
Sex: men/women, n (%)7647 (47.6) / 8403 (52.4)178,624 (46.0) / 210,007 (54.0)4220 (40.6) / 6178 (59.4)
BMI (kg/m2): median (IQR)26.0 (23.7–28.8)26.7 (24.2–29.9)25.1 (22.8–27.7)
BMI

  • Normal (≤ 25 kg/m2): n (%)

6207 (38.7)128,238 (33.0)5115 (49.2)

  • Overweight (25–30 kg/m2): n (%)

6978 (43.5)166,322 (42.8)3966 (38.1)

  • Obese (≥ 30 kg/m2): n (%)

2841 (17.7)94,141 (24.2)1316 (12.7)
Waist circumference

  • Men (cm): median (IQR)

94.0 (88.0–101.0)96.0 (89.0–104.0)94.0 (87.0–101.0)

  • Women (cm): median (IQR)

80.0 (74.0–88.0)83.0 (75.0–92.0)84.0 (77.0–93.0)
Metabolic comorbid diseases

  • T2DM: n (%)

449 (2.8)19,040 (4.9)235 (2.3)

  • MetS: n (%)

1827 (11.4)67,304 (17.3)1440 (13.8)
Hepatic fat content phenotypes
FLI: median (IQR)38.8 (16.2–67.3)46.4 (20.0–75.7)23.6 (9.8–51.0)

  • FLI < 30: n (%)

6333 (39.5)137,611 (35.4)6002 (57.7)

  • FLI ≥ 60: n (%)

4721 (29.4)149,672 (38.5)1988 (19.1)
MRI-PDFF (%): median (IQR)2.8 (1.9–5.2)N.A.N.A.

Note: Data are given in number with percentage (%) or median with IQR. T2DM was confirmed when a subject had either self-reported on T2DM, used glucose lowering medication, had fasting glucose ≥ 7.0 mmol/l, or had HbA1c ≥ 47.5 mmol/mol (6.5%). Metabolic syndromes were defined according to NCEP ATPIII criteria. UKBB MRI-PDFF imaging cohort includes UKBB imaging subset 1 (Data field 22436) and UKBB imaging subset 2 (return data ID 2342). MRI-PDFF, magnetic resonance imaging proton density fat fraction; FLI, fatty liver index; UKBB, UK Biobank; UMCG, University Medical Center Groningen; UGLI, UMCG Genetics Lifelines Initiative; IQR, interquartile range; BMI, body mass index; T2DM, type 2 diabetes mellitus; MetS, metabolic syndrome; NCEP, National Cholesterol Education Program; N.A., not available.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close